ABSTRACT
Cardiovascular disease is one of the leading global causes of morbidity and mortality worldwide. Obesity has been linked to several cardiovascular diseases, including coronary artery disease, atrial fibrillation, heart failure (HF), hypertension, and stroke. Several observational studies and some randomized trials have demonstrated that metabolic/bariatric surgery (MBS) reduces not only all-cause mortality but also mortality from coronary artery disease, myocardial infarction, and HF. Additionally, MBS is associated with a lower incidence of new-onset cardiovascular disease and improvements in HF, hypertension, and atrial fibrillation when compared to patients with obesity that are managed with pharmacologic therapy alone.
